New Triple-Threat attack on spreading breast cancer
NCT ID NCT02778685
Summary
This study is testing whether adding an immunotherapy drug (pembrolizumab) to two standard breast cancer medications improves outcomes for postmenopausal women whose estrogen-driven breast cancer has spread. The goal is to see if this three-drug combination can shrink tumors and control the cancer for longer. The trial enrolled 47 participants with newly diagnosed metastatic, hormone-receptor-positive breast cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Antelope Valley
Lancaster, California, 93534, United States
-
City of Hope Corona
Corona, California, 92879, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope Mission Hills
Mission Hills, California, 91345, United States
-
City of Hope South Pasadena
South Pasadena, California, 91030, United States
-
City of Hope Upland
Upland, California, 91786, United States
-
City of Hope West Covina
West Covina, California, 91790, United States
Conditions
Explore the condition pages connected to this study.